Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an announcement.
Botanix Pharmaceuticals Limited announced the cessation of Matthew Callahan as a director, effective May 23, 2025. The announcement details Callahan’s interests in the company, including a significant holding of fully paid ordinary shares and performance rights. This change in directorship may impact the company’s governance and strategic direction, influencing stakeholder confidence and market perception.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of dermatology and antimicrobial products. The company aims to address unmet needs in skin health through innovative therapies.
Average Trading Volume: 10,516,008
Technical Sentiment Signal: Hold
Current Market Cap: A$742.5M
Find detailed analytics on BOT stock on TipRanks’ Stock Analysis page.